Published in Am J Geriatr Psychiatry on January 15, 2002
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
The role of autophagy in neurodegenerative disease. Nat Med (2013) 4.46
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci (2007) 3.91
The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest (2005) 2.51
The use of PET in Alzheimer disease. Nat Rev Neurol (2010) 2.13
Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A (2003) 2.13
Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol (2014) 1.86
Tracking Alzheimer's disease. Ann N Y Acad Sci (2007) 1.78
Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. Neuroimage (2007) 1.67
Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol (2009) 1.67
In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med (2004) 1.65
Differential FDDNP PET patterns in nondemented middle-aged and older adults. Am J Geriatr Psychiatry (2009) 1.62
Towards a pharmacophore for amyloid. PLoS Biol (2011) 1.58
Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx (2005) 1.58
Fluoro-pegylated (FPEG) imaging agents targeting Abeta aggregates. Bioconjug Chem (2007) 1.49
Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol (2008) 1.49
Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography. Eur J Nucl Med Mol Imaging (2014) 1.49
Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. Arch Gen Psychiatry (2009) 1.44
Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo? Eur J Nucl Med Mol Imaging (2004) 1.42
In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J Neurosci (2005) 1.42
Alzheimer's disease and mild cognitive impairment. Neurol Clin (2007) 1.39
Biomarkers of Alzheimer's disease. Neurobiol Dis (2008) 1.37
Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci U S A (2006) 1.34
Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease. NeuroRx (2004) 1.30
F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. J Med Chem (2005) 1.30
Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis Assoc Disord (2008) 1.30
Pathogenesis of Alzheimer's disease. Clin Interv Aging (2007) 1.27
Does Alzheimer's disease begin in the brainstem? Neuropathol Appl Neurobiol (2009) 1.26
Beta-amyloid deposition and the aging brain. Neuropsychol Rev (2009) 1.25
Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J Neurochem (2009) 1.21
Characterization of IMPY as a potential imaging agent for beta-amyloid plaques in double transgenic PSAPP mice. Eur J Nucl Med Mol Imaging (2004) 1.21
Magnetic resonance imaging characterization of brain structure and function in mild cognitive impairment: a review. J Am Geriatr Soc (2008) 1.20
Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents. Magn Reson Med (2004) 1.19
Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. Eur J Nucl Med Mol Imaging (2012) 1.18
Smart optical probes for near-infrared fluorescence imaging of Alzheimer's disease pathology. Eur J Nucl Med Mol Imaging (2008) 1.17
Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J Cell Mol Med (2008) 1.16
In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem (2008) 1.13
The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr Opin Neurol (2008) 1.11
Development and evaluation of compounds for imaging of beta-amyloid plaque by means of positron emission tomography. Eur J Nucl Med Mol Imaging (2008) 1.08
A review of imaging agent development. AAPS J (2009) 1.08
Advances in neuroimaging of traumatic brain injury and posttraumatic stress disorder. J Rehabil Res Dev (2009) 1.08
Asymptomatic Alzheimer's disease: a prodrome or a state of resilience? Curr Alzheimer Res (2011) 1.05
Traumatic brain injury: cause or risk of Alzheimer's disease? A review of experimental studies. J Neural Transm (Vienna) (2005) 1.03
Positron emission tomography of brain β-amyloid and τ levels in adults with Down syndrome. Arch Neurol (2011) 1.01
Brain imaging in the study of Alzheimer's disease. Neuroimage (2011) 0.97
Children of persons with Alzheimer disease: what does the future hold? Alzheimer Dis Assoc Disord (2008) 0.97
Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults. Am J Geriatr Psychiatry (2009) 0.97
Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimers Res Ther (2014) 0.96
Amyloid plaque imaging in vivo: current achievement and future prospects. Eur J Nucl Med Mol Imaging (2008) 0.96
Neurobiology of cognitive aging: insights from imaging genetics. Biol Psychol (2008) 0.96
[(18)F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2015) 0.95
PET-based molecular imaging in neuroscience. Eur J Nucl Med Mol Imaging (2003) 0.95
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol (2012) 0.94
Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Arch Neurol (2012) 0.94
Protein binding in patients with late-life depression. Arch Gen Psychiatry (2011) 0.94
Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. NeuroRx (2005) 0.94
BODIPY-based molecular probe for imaging of cerebral β-amyloid plaques. ACS Chem Neurosci (2012) 0.93
Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events. Neuroimage (2007) 0.93
Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC. J Neurol Neurosurg Psychiatry (2003) 0.93
Brain functional network in Alzheimer's disease: diagnostic markers for diagnosis and monitoring. Int J Alzheimers Dis (2011) 0.91
PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J Alzheimers Dis (2013) 0.91
Multimodal Imaging of Alzheimer Pathophysiology in the Brain's Default Mode Network. Int J Alzheimers Dis (2011) 0.91
Evaluation of tracer kinetic models for analysis of [18F]FDDNP studies. Mol Imaging Biol (2009) 0.90
Positron emission tomography scans obtained for the evaluation of cognitive dysfunction. Semin Nucl Med (2008) 0.90
Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 0.90
Synthesis and beta-amyloid binding properties of rhenium 2-phenylbenzothiazoles. Bioorg Med Chem Lett (2009) 0.90
Beta-amyloid imaging with florbetaben. Clin Transl Imaging (2015) 0.89
PET/CT in diagnosis of dementia. Ann N Y Acad Sci (2011) 0.89
Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer's brains. ACS Chem Neurosci (2011) 0.88
Synthesis and evaluation of two 18F-labeled 6-iodo-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridine derivatives as prospective radioligands for beta-amyloid in Alzheimer's disease. J Med Chem (2004) 0.88
Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue. Acta Neuropathol Commun (2015) 0.87
PET amyloid-beta imaging in preclinical Alzheimer's disease. Biochim Biophys Acta (2011) 0.87
Mapping brain beta-amyloid. Curr Opin Neurol (2009) 0.86
Mild cognitive impairment: historical development and summary of research. Dialogues Clin Neurosci (2004) 0.86
Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease. Neurosci Biobehav Rev (2014) 0.86
Synthesis and evaluation of novel chalcone derivatives with (99m)Tc/Re complexes as potential probes for detection of β-amyloid plaques. ACS Chem Neurosci (2010) 0.85
Recent advances in imaging Alzheimer's disease. J Alzheimers Dis (2013) 0.85
Characteristics of Tau and Its Ligands in PET Imaging. Biomolecules (2016) 0.85
[F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment. Neurobiol Dis (2011) 0.85
SPECT Imaging Agents for Detecting Cerebral β-Amyloid Plaques. Int J Mol Imaging (2011) 0.84
Fluorinated Benzofuran Derivatives for PET Imaging of β-Amyloid Plaques in Alzheimer's Disease Brains. ACS Med Chem Lett (2010) 0.84
Using biomarkers to improve detection of Alzheimer's disease. Neurodegener Dis Manag (2011) 0.84
Imaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging. Front Neurosci (2015) 0.84
Magnetic resonance imaging of Alzheimer's disease. Eur Radiol (2006) 0.84
Memory decline shows stronger associations with estimated spatial patterns of amyloid deposition progression than total amyloid burden. Neurobiol Aging (2013) 0.84
MR microimaging of amyloid plaques in Alzheimer's disease transgenic mice. Eur J Nucl Med Mol Imaging (2008) 0.83
Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings. Trends Cogn Sci (2013) 0.83
Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res Ther (2011) 0.82
Glyconanoparticle aided detection of β-amyloid by magnetic resonance imaging and attenuation of β-amyloid induced cytotoxicity. ACS Chem Neurosci (2013) 0.82
Flow optimization study of a batch microfluidics PET tracer synthesizing device. Biomed Microdevices (2011) 0.82
Small-molecule theranostic probes: a promising future in neurodegenerative diseases. Int J Cell Biol (2013) 0.82
Neuroimaging in repetitive brain trauma. Alzheimers Res Ther (2014) 0.81
Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. Eur J Nucl Med Mol Imaging (2015) 0.81
Glia maturation factor expression in hippocampus of human Alzheimer's disease. Neurochem Res (2013) 0.81
Rethinking on the concept of biomarkers in preclinical Alzheimer's disease. Neurol Sci (2016) 0.80
Postmortem 3-D brain hemisphere cortical tau and amyloid-β pathology mapping and quantification as a validation method of neuropathology imaging. J Alzheimers Dis (2013) 0.80
Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study. Eur J Nucl Med Mol Imaging (2016) 0.80
Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 0.80
Mood, cognition and in vivo protein imaging: the emerging nexus in clinical neuroscience. Int J Geriatr Psychiatry (2008) 0.80
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med (2006) 6.02
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Inverse consistent mapping in 3D deformable image registration: its construction and statistical properties. Inf Process Med Imaging (2005) 2.87
Multistep synthesis of a radiolabeled imaging probe using integrated microfluidics. Science (2005) 2.83
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol (2007) 2.77
Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat Clin Pract Oncol (2008) 2.61
Metabolic crisis without brain ischemia is common after traumatic brain injury: a combined microdialysis and positron emission tomography study. J Cereb Blood Flow Metab (2005) 2.52
Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med (2005) 2.36
Analysis of European mitochondrial haplogroups with Alzheimer disease risk. Neurosci Lett (2004) 2.36
Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2'-deoxycytidine analog. Nat Med (2008) 2.24
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol (2003) 2.01
Childhood absence epilepsy: behavioral, cognitive, and linguistic comorbidities. Epilepsia (2008) 1.99
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
Effects of a 14-day healthy longevity lifestyle program on cognition and brain function. Am J Geriatr Psychiatry (2006) 1.93
Depression and anxiety disorders in pediatric epilepsy. Epilepsia (2005) 1.87
Noninvasive glucose sensing. Anal Chem (2005) 1.84
Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology (2005) 1.75
18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med (2006) 1.74
Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. J Nucl Med (2005) 1.63
Tight glycemic control increases metabolic distress in traumatic brain injury: a randomized controlled within-subjects trial. Crit Care Med (2012) 1.62
Differential FDDNP PET patterns in nondemented middle-aged and older adults. Am J Geriatr Psychiatry (2009) 1.62
Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol (2006) 1.60
Brain network local interconnectivity loss in aging APOE-4 allele carriers. Proc Natl Acad Sci U S A (2011) 1.60
Towards a pharmacophore for amyloid. PLoS Biol (2011) 1.58
Molecular mechanisms of bone 18F-NaF deposition. J Nucl Med (2010) 1.57
Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease. Neurobiol Aging (2008) 1.49
Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol (2008) 1.49
Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. Arch Gen Psychiatry (2009) 1.44
A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke (2012) 1.42
Estimation of the 18F-FDG input function in mice by use of dynamic small-animal PET and minimal blood sample data. J Nucl Med (2007) 1.42
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet (2002) 1.36
Ordered-subsets linkage analysis detects novel Alzheimer disease loci on chromosomes 2q34 and 15q22. Am J Hum Genet (2003) 1.35
Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci U S A (2006) 1.34
Effects of administration route, dietary condition, and blood glucose level on kinetics and uptake of 18F-FDG in mice. J Nucl Med (2011) 1.31
In vivo quantitation of glucose metabolism in mice using small-animal PET and a microfluidic device. J Nucl Med (2007) 1.30
High-yield, automated radiosynthesis of 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile ([18F]FDDNP) ready for animal or human administration. Mol Imaging Biol (2007) 1.30
Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Arch Gen Psychiatry (2002) 1.30
Synthesis of a new heterobifunctional linker, N-[4-(aminooxy)butyl]maleimide, for facile access to a thiol-reactive 18F-labeling agent. Bioconjug Chem (2003) 1.28
Behavioral disorders in pediatric epilepsy: unmet psychiatric need. Epilepsia (2003) 1.28
PET scanning of brain tau in retired national football league players: preliminary findings. Am J Geriatr Psychiatry (2013) 1.27
Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. Proc Natl Acad Sci U S A (2009) 1.26
18F-fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging (2007) 1.25
Specificity of brain activation patterns in people at genetic risk for Alzheimer disease. Am J Geriatr Psychiatry (2002) 1.25
Requirement for deoxycytidine kinase in T and B lymphocyte development. Proc Natl Acad Sci U S A (2009) 1.23
Complementary use of tai chi chih augments escitalopram treatment of geriatric depression: a randomized controlled trial. Am J Geriatr Psychiatry (2011) 1.20
1-11C-acetate kinetics of prostate cancer. J Nucl Med (2008) 1.20
Psychopathology and pediatric complex partial seizures: seizure-related, cognitive, and linguistic variables. Epilepsia (2004) 1.19
A tracer kinetic model for 18F-FHBG for quantitating herpes simplex virus type 1 thymidine kinase reporter gene expression in living animals using PET. J Nucl Med (2004) 1.19
Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest. J Nucl Med (2011) 1.18
Repeat expansions in the C9ORF72 gene contribute to Alzheimer's disease in Caucasians. Neurobiol Aging (2012) 1.18
18F-FDOPA kinetics in brain tumors. J Nucl Med (2007) 1.18
3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med (2011) 1.18
Noninvasive measurement of myocardial activity concentrations and perfusion defect sizes in rats with a new small-animal positron emission tomograph. Circulation (2002) 1.18
Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain (2008) 1.18
Quantification of cerebral glucose metabolic rate in mice using 18F-FDG and small-animal PET. J Nucl Med (2009) 1.17
A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci (2013) 1.17
Frontal and temporal volumes in Childhood Absence Epilepsy. Epilepsia (2009) 1.15
Noninvasive measurement of cardiovascular function in mice with high-temporal-resolution small-animal PET. J Nucl Med (2006) 1.14
Accuracy of a method using short inhalation of (15)O-O(2) for measuring cerebral oxygen extraction fraction with PET in healthy humans. J Nucl Med (2004) 1.13
Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography. Cancer Gene Ther (2005) 1.13
Novel PET probes specific for deoxycytidine kinase. J Nucl Med (2010) 1.11
Structure-guided engineering of human thymidine kinase 2 as a positron emission tomography reporter gene for enhanced phosphorylation of non-natural thymidine analog reporter probe. J Biol Chem (2011) 1.10
Selective metabolic reduction in gray matter acutely following human traumatic brain injury. J Neurotrauma (2004) 1.09
Quantitative analysis of [18F]FDDNP PET using subcortical white matter as reference region. Eur J Nucl Med Mol Imaging (2009) 1.08